Skip to main content

Table 3 The indirect-comparison results of efficacy and safety of MAbs targeting CD38, SLAMF7 and PD-1/PD-L1 groups

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Outcomes Antibodies targeting CD38 vs SLAMF7 Antibodies targeting
CD38 vs PD-1/PD-L1
Antibodies targeting
SLAMF7 vs PD-1/PD-L1
PFR - HR(95CI) 0.662 (0.543,0.806) 0.317 (0.221,0.454) 0.479 (0.328,0.699)
OS - HR(95CI) 0.812 (0.584,1.127) NA NA
ORR - RR(95CI) 0.976 (0.763,1.248) 1.247 (1.035,1.503) 1.278 (0.968,1.688)
CR or better-RR(95CI) 2.253 (1.284,3.955) NA NA
VGPR or better-RR(95CI) 1.304 (0.956,1.778) NA NA
VGPR - RR(95CI) 0.993 (0.671,1.468) NA NA
PR- RR(95CI) 1.522 (0.876,2.642) NA NA
SD - RR(95CI) 0.636 (0.368,1.099) NA NA
Neutropenia - RR(95CI) 1.818 (1.41,2.344) 1.207 (0.94,1.55) 0.664 (0.515,0.855)
Anemia-RR(95CI) 0.932 (0.656,1.323) 0.566 (0.332,0.963) 0.607 (0.346,1.064)
Thrombocytopenia -RR(95CI) 1.186 (0.83,1.694) NA NA
Lymphopenia -RR(95CI) 1.043 (0.753,1.444) NA NA
Pneumonia-RR(95CI) 1.144 (0.72,1.817) 1.325 (0.725,2.419) 1.158 (0.58,2.311)
Diarrhea-RR(95CI) 1.00 (0.497,2.014) 0.446 (0.102,1.956) 0.446 (0.095,2.105)
Fatigue-RR(95CI) 1.681 (0.903,3.13) 5.00 (1.717,14.56) 2.975 (0.998,8.867)
  1. Abbreviations: PFS progression-free survival, OS overall survival, ORR overall response rate, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, HR hazard ratio, RR relative risk, NA not available